Hansa Biopharma — Juli 2022
-
Fra debatteb: https://www.proinvestor.com/boards/104550/
-
Hansa Biopharma AB: Hansa Biopharma half year report 2022
Hansa Biopharma half year report 2022
• Continued solid sales in Q2 • Positive NICE recommendation obtained • Completed
News Powered by Cision (news.cision.com)
-
Husk CC idag kl. 14:00.
The webcast will be available on:
-
Hansa Biopharma Q2; Idefirix sales progress and secured funding to end 2024
-
Hansa Biopharma AB (publ) (HNSBF) CEO Søren Tulstrup on Q2 2022 Results - Earnings Call Transcript
-
SEB:
Lift target price to SEK 260 (230)
We raise our Idefirix estimates on the back of the sales beat, and update ourmodel to reflect the financing from NovaQuest. Accordingly, we raise our SOTP-rNPV-based target price to SEK 260 (230) and reiterate our Buy rating". -
CARNEGIE OPJUSTER KURSMÅL TIL SEK 121.
ERIK PENSER BANK TIL SEK 240-250
RBC TIL SEK 171
-
Penser Access: Snygg finansieringslösning - Hansa Biopharma
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind